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Introduction 
Heart failure is a nation-wide epidemic with 5 million Americans affected, and it is the 
leading cause of death in the world.1,2 Cardiac transplantation is the current gold-
standard to treating end-stage heart failure.3 The one-year survival rate of cardiac 
transplantation is greater than 80% when patients are placed on an immunosuppressive 
regimen including medications such as corticosteroids, azathioprine, and cyclosporine 
A.3,4 Prior to the 1980s, success with cardiac transplantation was very limited. The 
introduction of cyclosporine A in 1980, when used in combination with azathioprine and 
corticosteroids, was the reason for the increase in one-year graft and patient survival.4 
The use of a three-drug regimen was became a main-stay in cardiac transplant 
recipients in the prophylaxis of acute rejection.5 
 
Shortly after 1980, tacrolimus was identified as a potential immunosuppressive agent 
that had comparable efficacy to cyclosporine A with significantly decreasing the 
incidence and severity of acute rejection following cardiac transplantion.6 In vivo and in 
vitro studies both suggest that cyclosporine A and tacrolimus operate through slightly 
different mechanisms. Tacrolimus is successful in providing ongoing prophylaxis of 
rejection due to the suppression of IL-10 and inhibition of IL-10-mediated cytotoxic cell 
infiltration into the transplant.7 There was no statistically significant difference in 
freedom from ISHLT Grade 3A rejection when using tacrolimus compared to 
cyclosporine.7 However tacrolimus demonstrated a better cardiovascular risk profile 
than cyclosporine A.7 
A newer randomized controlled open-label trial investigated the use of tacrolimus 
monotherapy to the use of tacrolimus in combination with mofetil mycophenolate (MMF) 
as prophylaxis of acute rejection in cardiac transplantation.7 The goal of this trial was to 
determine if outcomes were similar between monotherapy and combination groups. The 
primary outcome was the 6-month mean International Society of Heart and Lung 
Transplant (ISHLT) biopsy score, and the secondary outcomes included all-cause 
mortality, incidence of ISHLT grade 2R/3R rejection over 6- and 12-month time points, 
one-year mean cumulated ISHLT biopsy score, and incidence of allograft vasculopathy. 
The researchers found the incidence of 6-month freedom from rejection in the 
monotherapy group was 85.9% and in the combination group was 94.4%, but the 
findings were not statistically significant (p = 0.14). There was no significant reduction in 
rejection, allograft vasculopathy, or 3-year survival. 
 
The purpose of this project is to further establish the efficacy and safety of the use of 




This was a single arm, retrospective patient chart analysis of patients that received a 
cardiac transplant at UNC between 2006-2012. Patients were included if they were 18 
years of age or older, received a heart transplant between 2006-2012, and received 
tacrolimus monotherapy at some point for prevention of heart transplant. Patients were 
excluded if they were less than 18 years of age, were pregnant, or had multiple organs 
transplanted. Data was collected from existing medical records in Transchart and 
Webcis. The primary outcome of the research was the incidence of acute rejection at 6 
and 12 months post-monotherapy initiation. The secondary outcomes included adverse 
effects, graft survival, patient survival, and incidence of CMV viremia. Approval to 
conduct this research was obtained from UNC’s institutional research review board. 
 
Results 
Of all cardiac transplant recipients at UNC medical center, 29 patients had received 
tacrolimus monotherapy for some duration post-transplant. The average patient was a 
56 year-old Caucasian male who required a transplant due to non-ischemic 
cardiomyopathy (Table 1). 
Table 1. Patient demographics. 
Demographics N = 29 
Age (time of transplant, years ± SD) 56 ± 10 
Male, n (%) 24 (71%) 
Caucasian, n (%) 20 (71%) 
African American, n (%) 5 (18%) 
Primary Heart Disease: 
          Non-ischemic cardiomyopathy, n (%) 16 (55%) 
         Ischemic cardiomyopathy, n (%) 11 (39%) 
         Drug-induced, n (%) 1 (3%) 
         Congenital, n (%) 1 (3%) 
 
Most patients were placed on tacrolimus monotherapy due to good graft function (97%), 
and one patient was transitioned to monotherapy due to experiencing neutropenia from 
dual therapy with mycophenolate. The neutropenia did resolve after the removal of 
mycophenolate. The average time to initiating patients on monotherapy was 625 ±551 
days (median time to initiate monotherapy was 318 days with a range 137-2014). The 
average time patient remained on monotherapy was 799 ±544 days (median: 811, 
range 55-2140). Biopsy rejection scores at baseline were 0R in 15 patients (52%) and 
1R in 14 patients (48%). In patients with no evidence of rejection at baseline, 26.7% 
remained rejection-free at 6 months and 73% experienced some type of rejection 
(Figure 1). At 12 months a total of 27% were rejection-free, 20% had 1R rejection, 7% 
had 2R rejection, and 46% did not have a 12-month biopsy obtained. 
	  
Figure 1. Rejection status progression from 0R at baseline to 12 months. 
	  
Patients who were 0R at initiation of tacrolimus monotherapy and experienced a 
rejection episode were likely to experience their first rejection within the first 100 days 
(Figure 2). One patient continued to remain rejection-free at the end of 12 months.  
 
Patient characteristics of those who were rejection-free at 12 months were compared 
with those that experienced rejection at 6 and 12 months (Table 2.). There was no 
difference in age, gender, race or type of heart disease leading to transplantation. Mean 
tacrolimus levels were higher in those who had no rejection, 9 ±1.92, and trended down 
	   	  
	   	   	  
	   	   	  
in those who experienced 1R rejection at 6 months, 7.2 ±2.25, and 12 months, 5 ±1.15, 
and 2R rejection at 12 months, 6.1. Mean time to initiating monotherapy was also longer 
in those with no rejection at 12 months, 2.19 ±1.58 years, than those who experienced 
1R rejection at 6 months, 1.31 ±1.44 years, and at 12 months, 0.87 ±0.05 years, and 2R 
rejection at 12 months, 0.59 years. 
 
 




















Tacrolimus is an immunosuppressive therapy that requires therapeutic drug monitoring 
to assess the level of immunosuppression a patient receives. The length of time after 
transplant typically determines the optimal goal trough for tacrolimus, with 
recommended troughs to be 5-15 ng/mL in patients 4 months post-transplant.8 The 
higher the trough typically the greater level of immunosuppression a patient receives. 
The patients in this study who were rejection-free at 12 months had higher trough levels 
than those experiencing some level of rejection, which indicate they were more 
immunosuppressed. The higher level of immunosuppression contributes to the patient’s 
 
0R at 12 Mo. 
(N = 5) 
1R at 6 Mo. 
(N = 11) 
1R at 12 Mo. 
(N = 3) 
2R at 12 Mo. 
(N = 1) 
Age at time of transplant (years) 55.58 ±12.41 55.85 ±9.95 49.27 ±16.74 38.6 
Male, n (%) 4 (80%) 11 (100%) 3 (100%) 1 (100%) 
Caucasian, n (%) 4 (80%) 10 (91%) 2 (67%) 0 
African American, n (%) 1 (20%) 1 (9%) 1 (33%) 1 (100%) 
Non-ischemic cardiomyopathy, 
n (%) 4 (80%) 7 (64%) 2 (67%) 1 (100%) 
Ischemic cardiomyopathy, n (%) 1 (20%) 4 (36%) 1 (33%) 0 
Mean TAC level 30 days before 
biopsy (ng/mL) 9 ±1.92 7.2 ±2.25 5 ±1.15 6.1 
Resume dual/triple therapy after 
biopsy (%) 2 (40%) 4 (36%) 3 (100%) 1 (100%) 
Mean time to monotherapy 
(years) 2.19 ±1.58 1.31 ±1.44 0.87 ±0.05 0.59 
Mean time to starting TAC after 
transplant (days) 4 ±1.73 4.36 ±1.8 3.67 ±1.53 5 
Incidence of CMV viremia, n (%) 1 (20%) 2 (18%) 1 (33%) 0 
transplant having a lesser chance for acute rejection, which was seen in the results of 
this analysis. 
 
Another factor that can contribute to the stability of a transplant is the length of time 
post-transplant. Typically a transplant has a lower immunosuppression requirement the 
longer it is post-transplant. There was a clear trend in the data illustrating that more 
patients who were rejection-free at 12 months were placed on monotherapy when they 
were more than two years from transplant. The one patient that experienced 2R 
rejection at 12 months was initiated on monotherapy within the first year of receiving the 
transplant. The patient’s transplant was likely at greater risk for acute rejection, and the 
removal of all but one immunosuppressive therapy further increased the risk of rejection 
due to not receiving adequate immunosuppression. 
 
This study has several limitations that we were aware of during data analysis. First the 
sample size is very small, making it difficult to draw conclusive evidence and apply it to 
clinical practice. Secondly there was no protocol in place for initiating patients on 
monotherapy, so the process for placing patients on monotherapy was not 
standardized. This was an issue because biopsy results were not taken at regular 
intervals and data was missing at 6- and 12-month time points for some patients, and 
this resulted in less data that could be analyzed. The study is also of a retrospective 
nature, so this made it impossible to assess patient adherence to tacrolimus since it 
was not always recorded in patient charts. It also could not be determined if rates of 
rejection seen in the trial were what should be expected, as there was a lack of a 
comparator group.  
 
Conclusion 
From this study we conclude that tacrolimus monotherapy should be considered in 
patients who are healthy, adherent to their immunosuppressive therapies, and have a 
low risk for rejection. These patients should be at least two years post-transplant and 
should have a reduced immunosuppressive requirement. There are limitations to this 
study that make it difficult to generalize this to the transplant population. Follow up 
studies could include a prospectively designed trial with a study and control arm and a 
strict protocol for monitoring immunosuppression adherence and obtaining biopsies on 
a scheduled basis. 
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